Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1078

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 5
Chunk 1078
---
    Director

Biographic
Information 

Francis
Knuettel II has served as our Chief Executive Officer since July 2023, as our Chief Financial Officer, Treasurer and Secretary
since June 2022, as our Chief Executive Officer since March 2024, and has served as a member of our board of directors since August
2024. Prior to that, from December 2020 to April 2022, he served as Chief Executive Officer and director of Unrivaled Brands,
a California-based operator of cannabis assets in California and Oregon, where he helped grow revenue from an annualized rate
of $10 million to $100 million in six quarters by acquiring three companies in the sector. He also served as Chief Financial Officer
of ONE Cannabis Group from June 2019 to January 2021 and held various roles at MJardin Group, including Chief Strategy Officer,
from August 2018 to January 2019. Prior to MJardin Group, Mr. Knuettel served as Chief Financial Officer of Aqua Metals in 2018
and held the same position at Marathon Patent Group from 2014 to 2018. During Mr. Knuettel’s career, he has helped raise
more than $300 million via venture equity and debt, public equity and debt offerings in the United States and Canada, convertible
debt, PIPEs, bridge loans and other instruments. In addition, he has managed more than 15 mergers and acquisition transactions
of companies as both buyer and seller and has handled large-scale licensing transactions with fortune 50 companies. Mr. Knuettel
is also a board member at Etheros Pharmaceuticals Corp. since 2023. Mr. Knuettel received his BA with honors in Economics from
Tufts University and holds an MBA in Finance and Entrepreneurial Management from The Wharton School at the University of Pennsylvania.

82 

Eric
Lang has served as our Chief Medical Officer since May 2023. Prior to that, from September 2018 to May 2023, Dr.
Lang served at Nevakar Inc, initially as Vice President of Clinical Development and later as its Chief Medical Officer. From January
2018 to September 2018, Dr. Lang served as the Chief Medical Officer at Entera Bio Ltd. (Nasdaq: ENTX). From February 2012 to
November 2017, he served at Covance (now Labcorp Drug Development), heading an international team that assisted smaller biotech
companies in moving their programs